Kamada/$KMDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Ticker
$KMDA
Sector
Primary listing
Employees
420
Headquarters
Rehovot, Israel
Website
Kamada Metrics
BasicAdvanced
$401M
21.24
$0.32
0.06
$0.20
5.88%
Price and volume
Market cap
$401M
Beta
0.06
52-week high
$9.16
52-week low
$5.18
Average daily volume
58K
Dividend rate
$0.20
Financial strength
Current ratio
4.004
Quick ratio
2.211
Long term debt to equity
3.673
Total debt to equity
4.391
Dividend payout ratio (TTM)
60.67%
Interest coverage (TTM)
34.11%
Profitability
EBITDA (TTM)
38.445
Gross margin (TTM)
43.62%
Net profit margin (TTM)
11.21%
Operating margin (TTM)
14.89%
Effective tax rate (TTM)
-1.27%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
4.39%
Return on equity (TTM)
7.44%
Valuation
Price to earnings (TTM)
21.242
Price to revenue (TTM)
2.308
Price to book
4.96
Price to tangible book (TTM)
9.92
Price to free cash flow (TTM)
12.387
Free cash flow yield (TTM)
8.07%
Free cash flow per share (TTM)
0.549
Dividend yield (TTM)
2.94%
Forward dividend yield
5.88%
Growth
Revenue change (TTM)
9.67%
Earnings per share change (TTM)
27.97%
3-year revenue growth (CAGR)
16.87%
10-year revenue growth (CAGR)
9.21%
3-year earnings per share growth (CAGR)
6.82%
10-year earnings per share growth (CAGR)
2.05%
What the Analysts think about Kamada
Analyst ratings (Buy, Hold, Sell) for Kamada stock.
Bulls say / Bears say
Kamada posted 11% year-over-year revenue growth to $88.8 million in H1 2025, with adjusted EBITDA up 35% to $22.5 million. This led to an upward revision of its full-year adjusted EBITDA guidance to $40–$44 million, while maintaining revenue guidance of $178–$182 million (Nasdaq).
In August 2025, the U.S. FDA approved Kamada’s Houston plasma collection center for commercial sales of normal source plasma, with an annual capacity of around 50,000 liters and potential revenue of $8–$10 million at full capacity (Nasdaq).
Benchmark started coverage of Kamada with a Buy rating and a $14.96 average one-year price target, representing a 122.45% upside from the then-current share price, reflecting strong analyst confidence (Nasdaq).
Kamada’s Q2 2025 revenues came in at $44.75 million, just below the Zacks Consensus estimate of $45.06 million, missing by 0.67%, suggesting possible headwinds in sales momentum (Nasdaq).
Gross margin dropped to 42% in Q2 2025 from 45% in the previous year, reflecting a less favorable product sales mix and putting pressure on profitability (Nasdaq).
Operating cash flow fell to $8.0 million in Q2 2025 from $14.0 million in Q2 2024. Cash and cash equivalents decreased to $66.0 million as of June 30, 2025, compared to $78.4 million at the end of 2024, signaling tighter liquidity (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Kamada Financial Performance
Revenues and expenses
Kamada Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kamada stock?
Kamada (KMDA) has a market cap of $401M as of October 12, 2025.
What is the P/E ratio for Kamada stock?
The price to earnings (P/E) ratio for Kamada (KMDA) stock is 21.24 as of October 12, 2025.
Does Kamada stock pay dividends?
Yes, the Kamada (KMDA) stock pays dividends to shareholders. As of October 12, 2025, the dividend rate is $0.2 and the yield is 5.88%. Kamada has a payout ratio of 60.67% on a trailing twelve-month basis.
When is the next Kamada dividend payment date?
The next Kamada (KMDA) dividend payment date is unconfirmed.
What is the beta indicator for Kamada?
Kamada (KMDA) has a beta rating of 0.06. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.